The Kidney–Obesity Interface — Education
Where kidney medicine meets obesity medicine.
An evidence-based educational resource for clinicians caring for patients where kidney disease and obesity meet. It offers a structured curriculum, a source-bound study library, and teaching cases.
Nephrobesity is an independent educational resource. It curates and teaches published evidence at the intersection of nephrology and obesity medicine. It does not represent a board specialty, a medical society, or clinical guidance for individual patients.
Why it exists
When kidney function is reduced, what changes is the clinical context around these drugs — not, for the main incretin agents, their dosing.
The principal incretin agents — semaglutide and tirzepatide — need no renal dose adjustment, so the issues in reduced kidney function are not about drug accumulation but about volume status, how creatinine and eGFR read, and when to hold co-prescribed RAASi, diuretics, and SGLT2 inhibitors. Several standard assumptions need a second look:
Four areas of expertise
Four domains of expertise at the intersection.
Nephrobesity brings together the pharmacology, physiology, and clinical judgment needed when kidney disease and obesity coexist.
Incretin and CKM pharmacology, with renal safety
Semaglutide, SGLT2 inhibitors, and finerenone — renal-outcome evidence, dosing, monitoring, and the safety questions the trials leave open.
The protein dilemma
Balancing weight-loss nutrition against protein needs in CKD, dialysis, and post-transplant patients.
Obesity-related glomerulopathy
Once ORG is separated from primary FSGS, treating the obesity — weight loss, RAAS blockade, SGLT2 — becomes the kidney therapy.
Cardiovascular-kidney-metabolic (CKM)
Placing the kidney inside the CKM continuum that now organizes prevention and therapy.
Journal watch
Evidence library.
Semaglutide slows kidney disease in type 2 diabetes (FLOW)
In people with type 2 diabetes and chronic kidney disease, weekly semaglutide reduced major kidney events by 24% versus placebo.
Kidney outcomes with semaglutide in obesity without diabetes (SELECT)
A prespecified secondary analysis within a cardiovascular-outcomes trial found a lower composite kidney endpoint with semaglutide in adults with obesity and cardiovascular disease but no diabetes.
Semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE)
At 72 weeks (planned interim analysis), more patients on semaglutide achieved resolution of steatohepatitis without worsening fibrosis than on placebo — liver (MASH) evidence within the CKM continuum.
Teaching cases
Cases at the bedside.
Short, source-linked teaching cases that show how the standard rules change when kidney function is reduced — from euglycemic DKA to GFR estimation and the protein dilemma.
About the editor
Edited by Amir Naderi, MD.
Nephrobesity is curated and maintained by Amir Naderi, MD — a nephrologist and internist with dual American Board of Internal Medicine certification in Internal Medicine and Nephrology, Fellow of the American Society of Nephrology (FASN), who selects and teaches the published evidence at the kidney–obesity intersection.
Journal watch, curated
New evidence, explained plainly.
A periodic note when a study meaningfully changes how we think about the kidney–obesity axis. No promotion, no filler.
For patients
Taking a weight-loss medication, or thinking about it? Start with the plain-language basics: what the studies show, common myths, and the safety rules that matter.